

Special Issue

Adoptive T-Cell Therapy against Solid Tumors

Message from the Guest Editor

Tumor-antigen-specific cytotoxic T lymphocytes (CTL) play a key role in tumor immunology. Therefore, the generation of these cells to support the often-crippled immune system of the patient has been the main aim in the cellular adoptive immunotherapy of cancer. The transferred cells range from tumor-infiltrating lymphocytes (TIL) to T cells reprogrammed with a tumor-antigen specificity by transfer of a T-cell receptor (TCR) or chimeric antigen receptor (CAR). The latter strategy in particular has proven to be very efficient in the treatment of hematologic tumors. However, the efficacy against solid tumor lags behind. Therefore, this Special Issue will focus on improvements and new strategies of adoptive T-cell therapy against solid tumors. Authors are cordially invited to contribute original research papers or reviews to this Special Issue of *Immuno*. For further information about the topics of interest, please visit:

https://www.mdpi.com/journal/immuno/special_issues/tcell
Dr. Dr. habil. med. Niels Schaft

Guest Editor

Prof. Dr. Niels Schaft

Department of Dermatology, Universitätsklinikum Erlangen, 91054 Erlangen, Germany

Deadline for manuscript submissions

closed (30 November 2022)



Immuno

an Open Access Journal
by MDPI

Impact Factor 2.1
CiteScore 2.6



[mdpi.com/si/54368](https://www.mdpi.com/si/54368)

Immuno
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
immuno@mdpi.com

[mdpi.com/journal/
immuno](https://www.mdpi.com/journal/immuno)





Immuno

an Open Access Journal
by MDPI

Impact Factor 2.1
CiteScore 2.6



[mdpi.com/journal/
immuno](https://mdpi.com/journal/immuno)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Toshihiko Torigoe
Department of Pathology, Sapporo Medical University School of
Medicine, S-1, W-17, Chuo-ku, Sapporo 060-8556, Japan

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid
by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), Scopus, EBSCO,
and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 28.1 days after
submission; acceptance to publication is undertaken in 5.5
days (median values for papers published in this journal in
the first half of 2024).